MX2019005005A - Tableta de liberacion extendida que comprende un farmaco de perdida de peso. - Google Patents

Tableta de liberacion extendida que comprende un farmaco de perdida de peso.

Info

Publication number
MX2019005005A
MX2019005005A MX2019005005A MX2019005005A MX2019005005A MX 2019005005 A MX2019005005 A MX 2019005005A MX 2019005005 A MX2019005005 A MX 2019005005A MX 2019005005 A MX2019005005 A MX 2019005005A MX 2019005005 A MX2019005005 A MX 2019005005A
Authority
MX
Mexico
Prior art keywords
extended release
release tablet
weight
loss drug
pharmaceutically acceptable
Prior art date
Application number
MX2019005005A
Other languages
English (en)
Inventor
Stroppolo Federico
Granata Gabriele
Original Assignee
Alpex Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpex Pharma Sa filed Critical Alpex Pharma Sa
Publication of MX2019005005A publication Critical patent/MX2019005005A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen una tableta de liberación prolongada (ERT), que comprende fentermina o una de sus sales farmacéuticamente aceptables y una o más de una cera y al menos un excipiente farmacéuticamente aceptable seleccionado entre uno o más de un ácido graso, un agente de carga, un lubricante y similares y un proceso para su preparación.
MX2019005005A 2016-11-08 2017-11-07 Tableta de liberacion extendida que comprende un farmaco de perdida de peso. MX2019005005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16197747.5A EP3318252A1 (en) 2016-11-08 2016-11-08 Extended release tablet comprising a weight-loss drug
PCT/EP2017/078500 WO2018087097A1 (en) 2016-11-08 2017-11-07 Extended release tablet comprising a weight-loss drug

Publications (1)

Publication Number Publication Date
MX2019005005A true MX2019005005A (es) 2019-06-20

Family

ID=57256151

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005005A MX2019005005A (es) 2016-11-08 2017-11-07 Tableta de liberacion extendida que comprende un farmaco de perdida de peso.

Country Status (9)

Country Link
US (1) US11744809B2 (es)
EP (2) EP3318252A1 (es)
CN (1) CN110022868B (es)
AU (1) AU2017258853B2 (es)
CA (1) CA3037856A1 (es)
MX (1) MX2019005005A (es)
NZ (1) NZ737099A (es)
WO (1) WO2018087097A1 (es)
ZA (1) ZA201707549B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3318252A1 (en) 2016-11-08 2018-05-09 Alpex Pharma SA Extended release tablet comprising a weight-loss drug

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2006104397A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
US9125833B2 (en) * 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
CA2617688C (en) * 2007-02-22 2015-08-18 Alpex Pharma S.A. Solid dosage formulations containing weight-loss drugs
AU2010295307B2 (en) * 2009-06-12 2014-11-20 Pharmacorp (Pty) Ltd Phentermine liquid dosage form
EP3318252A1 (en) 2016-11-08 2018-05-09 Alpex Pharma SA Extended release tablet comprising a weight-loss drug

Also Published As

Publication number Publication date
ZA201707549B (en) 2018-11-28
AU2017258853B2 (en) 2019-05-16
CN110022868A (zh) 2019-07-16
WO2018087097A1 (en) 2018-05-17
US20190254993A1 (en) 2019-08-22
AU2017258853A1 (en) 2018-05-24
US11744809B2 (en) 2023-09-05
CA3037856A1 (en) 2018-05-17
EP3538082A1 (en) 2019-09-18
EP3318252A1 (en) 2018-05-09
CN110022868B (zh) 2022-09-16
NZ737099A (en) 2022-05-27

Similar Documents

Publication Publication Date Title
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
MX2018002462A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
MY175387A (en) Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
PH12017502249A1 (en) Tofacitinib orally disintegrating tablets
PH12016501841A1 (en) Immunosuppressant formulation
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2020013162A (es) Comprimidos de liberacion inmediata que contienen un farmaco y procesos para formar los comprimidos.
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
MX2019005005A (es) Tableta de liberacion extendida que comprende un farmaco de perdida de peso.
PH12016501205B1 (en) Catecholamine production accelerator, and therapeutic and preventive agent and therapeutic and preventive food composition for diseases caused by catecholamine deficiency
JOP20180071A1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
EP4342542A3 (en) Combination of regorafenib and nivolumab for treating cancer
EP3593805A4 (en) USE OF A VITAMIN COMPOSITION IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION, TREATMENT OR DELAY OF ALZHEIMER'S DISEASE
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
UA124942C2 (uk) Спосіб одержання енантіомерів пірліндолу та їхніх солей
MX2017008931A (es) Formulaciones farmaceuticas de xantina o derivados de xantina.
PH12016502527B1 (en) Stabilized desmopressin
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
PH12019501689A1 (en) Composition comprising immediate release and extended release capecitabine